Abstract

Core B ? Abstract In this adjuvant-enhanced and electroporation-delivered DNA prime-protein boost HIV vaccine development program, the availability of high-quality and well-developed recombinant Env protein vaccine components are critical to the success of entire program. Core B is designed to provide non-GMP recombinant Env proteins for proposed pre-clinical animal studies, including non-human primate studies, and to advise on scientific and technical issues related to the production of GMP-grade recombinant Env proteins for planned phase I clinical studies. The PI of Core B, Dr. Shan Lu, has developed a polyvalent gp120 protein formulation from his previous NIH-funded programs. That formulation includes four recombinant gp120 proteins (covering HIV-1 subtypes A, B, C, and AE) produced using the CHO system under GMP conditions.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109646-01A1
Application #
8892529
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Project Start
Project End
2016-02-29
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
1
Fiscal Year
2015
Total Cost
$447,875
Indirect Cost
$45,878

  Institution

Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Schultheis, Katherine; Smith, Trevor R F; Kiosses, William B et al. (2018) Delineating the Cellular Mechanisms Associated with Skin Electroporation. Hum Gene Ther Methods 29:177-188
Xu, Ziyang; Wise, Megan C; Choi, Hyeree et al. (2018) Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig. EBioMedicine 35:97-105
Wang, Shixia; Chou, Te-Hui; Hackett, Anthony et al. (2017) Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. Hum Vaccin Immunother 13:2996-3009
Fisher, P D; Brambila, C J; McCoy, J R et al. (2017) Adipose tissue: a new target for electroporation-enhanced DNA vaccines. Gene Ther 24:757-767
Tebas, Pablo; Roberts, Christine C; Muthumani, Kar et al. (2017) Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med :
Smith, Trevor R F; Schultheis, Katherine; Broderick, Kate E (2017) Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods. Hum Vaccin Immunother 13:2626-2629
Smith, Trevor R F; Schultheis, Katherine; Morrow, Matthew P et al. (2017) Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus. Vaccine 35:2840-2847
Ake, Julie A; Schuetz, Alexandra; Pegu, Poonam et al. (2017) Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost. J Infect Dis 216:1080-1090
Griffiths, Kristin L; Villarreal, Daniel O; Weiner, David B et al. (2016) A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis. Hum Vaccin Immunother 12:2649-2653
Kutzler, M A; Wise, M C; Hutnick, N A et al. (2016) Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. Mucosal Immunol 9:13-23

Showing the most recent 10 out of 14 publications